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Background: Neisseria gonorrhoeae  antibiotic 
resistance surveillance is important to maintain 
adequate treatment. We analysed 2007–15 data 
from the Gonococcal Resistance to Antimicrobials 
Surveillance (GRAS), which currently includes 19 of 
25 sexually transmitted infection (STI) centres in 
the Netherlands.  Methods: From each patient with 
a gonorrhoea culture, the minimum inhibitory con-
centration (MIC) for several antibiotics was deter-
mined. Time trends were assessed by geometric 
means and linear regression of logarithmic MIC. 
Determinants for decreased susceptibility to ceftriax-
one (MIC > 0.032 mg/L) and resistance to cefotaxime 
(MIC > 0.125 mg/L) and azithromycin (MIC > 0.5 mg/L) 
were assessed using stratified logistic regres-
sion.  Results: 11,768 isolates were analysed. No cef-
triaxone resistance was found. In 2015, 27 of 1,425 
isolates (1.9%) were resistant to cefotaxime and 176 
of 1,623 (10.9%) to azithromycin. Ceftriaxone suscep-
tibility showed no trend (p = 0.96) during the study 
period, but cefotaxime MIC decreased (p < 0.0001) 
and azithromycin MIC increased (p < 0.0001) signifi-
cantly. Concerning ceftriaxone, isolates of men who 
have sex with men (MSM) from 2013 (p = 0.0005) and 
2014 (p = 0.0004) were significantly associated with 
decreased susceptibility. Significant determinants 
for cefotaxime resistance were having ≥ 6 partners for 
women (p = 0.0006). For azithromycin,isolates from 
MSM collected in 2012 (p = 0.0035), 2013 (p = 0.012), 
and 2014 (p = 0.013), or from non-Dutch (p < 0.0001) 
or older (≥ 35 years; p = 0.01) MSM were significantly 
associated with susceptibility. Resistance in hetero-
sexual men was significantly associated with being 
≥ 25 years-old (p = 0.0049) or having 3–5 partners 
(p = 0.01). Conclusions: No ceftriaxone resistance was 
found, but azithromycin MIC increased in 2007–15. 
Resistance determinants could help with focused 
intervention strategies.
Introduction
Gonorrhoea, caused by  Neisseria gonorrhoeae, is one 
of the most common sexually transmitted infections 
(STI) and, with increasing resistance, a major public 
health concern globally [1]. Gonorrhoea is the second 
most common bacterial STI in the Netherlands. Under 
the national sentinel surveillance programme in STI 
centres, 5,391 cases were reported in 2015, and gonor-
rhoea was most prevalent among men who have sex 
with men (MSM): 10.7 per cent tested positive for gon-
orrhoea compared with 1.9 per cent and 1.6 per cent in 
heterosexual men and women respectively [2].
Third generation (3G) cephalosporins, such as ceftriax-
one and cefixime (and cefotaxime in the Netherlands), 
are routinely used for the treatment of gonorrhoea in 
most countries. In the Netherlands, cefotaxime became 
the first-line therapy for gonorrhoea in 2003 and cef-
triaxone in 2006 [3]. However, the susceptibility of 
gonococci to these cephalosporins has been decreas-
ing and  N. gonorrhoeae  has developed antimicrobial 
resistance (AMR) to most drugs used for treatment. 
Several treatment failures for 3G cephalosporins have 
been reported; cefixime treatment failures have been 
verified in several countries [4-10]. In the Netherlands, 
treatment failure with cefotaxime has been reported 
once so far [11]. A 2012 European guideline subse-
quently advised to exclude cefixime and cefotaxime 
from the first-line antimicrobial treatment recommen-
dations [12].
The present first-line treatment of choice in most coun-
tries worldwide is ceftriaxone, often combined in dual 
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therapy with azithromycin [12-14]. In the Netherlands, 
it was decided in 2012 to only advise single therapy 
ceftriaxone (500 mg) [15], which is in accordance with 
the 2016 World Health Organization (WHO) guidelines 
[14]. However, outside of the Netherlands, resistance 
and treatment failures have been described for both 
drugs [16-22]. The first high-level azithromycin-resist-
ant gonorrhoea was reported in the United Kingdom 
(UK) in 2015 [23]. Moreover, the first treatment fail-
ure on dual therapy of azithromycin and ceftriaxone 
was reported in 2016 in the UK [24]. This rapid devel-
opment of  N. gonorrhoeae  resistance to antibiotics 
threatens effective treatment. Targeted surveillance of 
new resistance patterns and insights, both into their 
spread into sexual networks and in their determinants 
are essential to control this trend.
To maintain adequate and updated treatment and 
prevention guidelines, the Gonococcal Resistance to 
Antimicrobials Surveillance (GRAS) was implemented 
within the Dutch STI sentinel surveillance network in 
July 2006. The STI sentinel surveillance system has 
national coverage and all consultations and corre-
sponding diagnoses are reported online to the National 
Institute of Public Health and the Environment of the 
Netherlands (RIVM) for surveillance purposes, a process 
that is facilitated by a web-based application (SOAP) 
[2]. In this study, results of the GRAS surveillance are 
analysed, combining epidemiological and microbiologi-
cal data to focus on trends in antimicrobial susceptibil-
ity of N. gonorrhoeae in the Netherlands between 2007 
and 2015. We also identified determinants associated 
with decreased ceftriaxone susceptibility as well as 
azithromycin and cefotaxime resistance.
Table 1
Characteristics of gonorrhoea patients from Dutch sexually transmitted infection centres with culture-positive Neisseria 
gonorrhoeae, by sexual orientation, 2007–2015 (n = 11,768 consultations)
Characteristic
MSM 
 
(n = 7,488)
Heterosexual men (n = 2,526)
Women 
 
(n = 1,754)
Total 
 
(N = 11,768)
n % n % n % n %
Year of diagnosis
2007 572 7.6 227 9.0 133 7.6 932 7.9
2008 635 8.5 184 7.3 110 6.3 929 7.9
2009 694 9.3 247 9.8 156 8.9 1,097 9.3
2010 762 10.2 301 11.9 171 9.8 1,234 10.5
2011 837 11.2 351 13.9 239 13.6 1,427 12.1
2012 980 13.1 394 15.6 238 13.6 1,612 13.7
2013 1,006 13.4 294 11.6 247 14.1 1,547 13.2
2014 1,005 13.4 299 11.8 244 13.9 1,548 13.2
2015 997 13.3 229 9.1 216 12.3 1,442 12.3
Age (years)
< 25 1247 16.7 1017 40.3 1159 66.1 3,423 29.1
25–35 2601 34.7 939 37.1 375 21.4 3,915 33.3
≥ 35 3,640 48.6 570 22.6 220 12.6 4,430 37.6
Ethnicity
Dutch 3,189 42.6 1,030 40.8 773 44.1 4,992 42.4
Non-Dutch 4,299 57.4 1,496 59.2 981 55.9 6,776 57.6
CSW (for MSM or women)
No 7,281 97.2
NA NA
1,498 85.4 8,779 74.6
Yes, in past 6 months 176 2.4 252 14.4 428 3.6
Unknown 31 0.4 4 0.2 35 0.3
Client of CSW (for men including MSM)
No 7,362 98.3 2,210 87.5
NA NA
9,572 81.3
Yes, in past 6 months 74 1.0 309 12.2 383 3.3
Unknown 52 0.7 7 0.3 59 0.5
New HIV infection
No 7,250 96.8 2,516 99.6 1,752 99.9 11,518 97.9
Yes 238 3.2 10 0.4 2 0.1 250 2.1
CSW: commercial sex worker; MSM: men who have sex with men.
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Methods
GRAS includes data from STI centres across the 
Netherlands and from laboratories connected to STI 
centres, as well as laboratories that also test other 
patients. The STI centres provide free STI testing and 
care to people in specified high-risk groups, e.g. MSM 
and people < 25 years-old [2]. Patients who are not part 
of a specified high-risk group are referred to their gen-
eral practitioner (GP) for STI testing and care, which is 
not free for low-risk groups. Currently, GRAS includes 
19 of a total 25 STI centres in the Netherlands.
Figure 1
Distribution of minimum inhibitory concentration values for azithromycina, cefotaxime and ceftriaxonea susceptibility of 
Neisseria gonorrhoeae from patients of Dutch sexually transmitted infection centres, 2007–2015
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EUCAST: European Committee on Antimicrobial Susceptibility Testing; GRAS: Gonococcal Resistance to Antimicrobials Surveillance.
The arrows indicate the threshold for antimicrobial resistance according to EUCAST guidelines.
a Azithromycin and ceftriaxone were included in GRAS in 2011.
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Antimicrobial susceptibility testing
From each client who tests positive for gonorrhoea, a 
sample is requested for culture and susceptibility test-
ing. For GRAS, minimum inhibitory concentration (MIC) 
values are collected and reported in SOAP for each 
diagnosed gonorrhoea patient with a positive culture. 
The antimicrobial susceptibility of gonococcal isolates 
is tested locally at laboratories related to the STI cen-
tres. The isolates are tested for azithromycin, cefo-
taxime, ceftriaxone, ciprofloxacin and spectinomycin 
using Etest (bioMérieux, Marcy l’Etoile, France) deter-
mining the MIC. Azithromycin and ceftriaxone were 
included in GRAS in 2011. Because GRAS started in July 
2006 there are many missing data that year, therefore 
the analyses in this study were performed on results 
from 2007 up to and including 2015.
Study population
The study population consisted of all patients of par-
ticipating STI centres who were diagnosed with a  N. 
gonorrhoeaeinfection and where antimicrobial sus-
ceptibility data were available. When patients were 
positive for gonorrhoea on multiple sites and more 
than one culture was obtained, only one culture was 
included in GRAS. Laboratories were requested to 
report the isolate with the highest MIC and in case of 
equal MICs, the European Centre for Disease prevention 
and Control (ECDC) guideline for European Gonococcal 
Antimicrobial Surveillance Programme (EURO-GASP) 
reporting was used [25] giving the following order 
of preference when multiple sites were infected. For 
males: pharyngeal, rectal, urethral, other; for females: 
pharyngeal, cervical, other anogenital (high vaginal 
swab/rectal/urethral), other.
For each visitor an anonymous report is submitted con-
taining epidemiological and clinical data, as well as 
test results on a wide range of STI. Ethnicity is based on 
(parental) country of birth. A person is defined as native 
Dutch if both parents were born in the Netherlands. A 
test of cure is not generally recommended.
Since June 2014, an individual ID number is available 
in SOAP, which enables identification of individual 
patients and their subsequent consultations. All anal-
yses were performed using isolates collected dur-
ing individual consultations. Patients having multiple 
sequential infections could be included for each infec-
tious episode.
As this study uses national data from the GRAS sur-
veillance, the data mentioned in Wind et al. [26] and 
Heymans et al. [27], which is specific for Amsterdam, is 
reused in a wider context in this report as part of the 
dataset.
Data analysis
Descriptive analyses of the study population were per-
formed. The chi-squared test was used to assess the 
significance in differences among groups (MSM, heter-
osexual men and women). Time trends were assessed 
by calculating mean MICs as geometric means per year 
and by performing a linear regression analysis of the 
logarithmic MICs. The criteria used to define resist-
ance are those used by the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST) [28]. 
Because there were very few strains that reached the 
0.125 mg/L threshold of ceftriaxone resistance, for risk 
factor analysis, strains with a MIC > 0.032 mg/L for cef-
triaxone were regarded as having a decreased suscep-
tibility (the epidemiological cut-off value according to 
EUCAST [28]). Determinants for decreased suscepti-
bility for ceftriaxone (MIC > 0.032 mg/L) and resistance 
for cefotaxime (MIC > 0.125 mg/L) and azithromycin 
(MIC > 0.5 mg/L) were identified using logistic regression 
analyses. Since sexual orientation is highly correlated 
with many other variables, we performed separate 
analyses for MSM, heterosexual men and women. 
Table 2
Geometric mean minimum inhibitory concentration per year for cefotaxime, ceftriaxone and azithromycin, found at Dutch 
sexually transmitted infection centres, 2007–2015
Year
Geometric mean minimum inhibitory concentration (mg/L) (95% CI)
Total number of isolates
Cefotaxime Ceftriaxonea Azithromycina
2007 0.0195 (0.0180–0.0211) NAa NAa 932
2008 0.0171 (0.0157–0.0187) NAa NAa 929
2009 0.0163 (0.0149–0.0178) NAa NAa 1,097
2010 0.0143 (0.0131–0.0156) NAa NAa 1,234
2011 0.0099 (0.0092–0.0107) 0.0063 (0.0059–0.0066) 0.1595 (0.1492–0.1705) 1,427
2012 0.0089 (0.0084–0.0095) 0.0043 (0.0041–0.0046) 0.1058 (0.0994–0.1125) 1,612
2013 0.0096 (0.0090–0.0103) 0.0058 (0.0055–0.0062) 0.1518 (0.1430–0.1612) 1,547
2014 0.0097 (0.0091–0.0103) 0.0056 (0.0053–0.0059) 0.1726 (0.1641–0.1816) 1,548
2015 0.0083 (0.0078–0.0088) 0.0043 (0.0041–0.0046) 0.1729 (0.1630–0.1833) 1,442
CI: confidence interval; GRAS: Gonococcal Resistance to Antimicrobials Surveillance; NA: not available.
a Azithromycin and ceftriaxone were included in GRAS in 2011.
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Multivariable analyses using backward selection were 
performed using all variables with clinical and statisti-
cal (p < 0.2) importance in the univariable analyses. In 
the multivariable analysis, statistical significance was 
determined as p < 0.05. As we wanted to study trends 
over time, year of infection was always included in the 
model. All statistical analyses were performed using 
SAS software, version 9.4 (VMware, Inc).
Results
Between 2007 and 2015 susceptibility testing for  N. 
gonorrhoeae  was performed for 11,768 isolates, 
covering 41.8% of all patients (n = 28,175) diagnosed 
with gonorrhoea in participating STI centres in that 
period. Before June 2014, no information about 
sequential infections in individual patients was 
available. Since June 2014, the majority of patients 
(2,162/2,550; 84.8%) were included only once; 163 of 
2,550 patients (6.4%) were included twice; 103 of 2,550 
patients (4.0%) were included three times and 122 of 
2,550 patients (4.8%) were included with four to eight 
consultations. Of the 388 patients who were included 
more than once 357 (92.0%) were MSM.
Baseline characteristics of patients
Eighty-five per cent of the isolates included were 
collected from men (10,014/11,768). Sixty-four per 
cent (7,488/11,768) of the isolates were from MSM 
and 42.4% (4,992/11,768) were people of Dutch ori-
gin (Table 1).  Table 1  also shows that almost half 
of the MSM with an isolate were older than 35 years 
(3,640/7,488) whereas most women (66.1%) were 
younger than 25 years of age (1,159/1,754). Fourteen 
per cent of women (252/1,754) worked as commercial 
sex workers (CSW) and 12.2% of heterosexual men 
(309/2,526) were a client of a CSW. Most isolates came 
from the urban regions of the Netherlands; the region 
of Amsterdam accounted for 61.3% (7,214/11,768) 
of all isolates between 2007 and 2015 (Amsterdam 
accounted for 42.0% of all gonorrhoea diagnoses). 
Patients with a positive culture differed from patients 
with a negative culture or without culture regarding 
demographic characteristics. Supplement 1 shows 
the characteristics of all gonorrhoea patients from 
Dutch STI centres with and without an isolate for 
susceptibility testing. Patients with a positive culture 
were more often male, older, MSM, non-Dutch and 
human immunodeficiency virus (HIV) positive (data not 
shown). The total percentage of isolates available for 
susceptibility testing has decreased over time, from 
61.0% of all diagnoses in 2007 to 26.7% in 2015, due to 
an increase in the total number of tests, the limitations 
of the GRAS surveillance where only one isolate per 
patient can be reported and negative cultures. Overall, 
about half of the anal and cervical cultures was 
negative (50.3% (3,288/6,539) and 51.1% (1,214/2,376) 
respectively), the percentage of negative urethral 
cultures was slightly lower (39.8%; 2,894/7,267) while 
the highest percentage of negative cultures was for 
oral cultures (72.2%, 3,186/4,410).
Antimicrobial susceptibility over time
Figure 1 shows the distribution of MIC values over time 
for azithromycin (Figure 1A), cefotaxime (Figure 1B), 
and ceftriaxone (Figure 1C). For azithromycin, the high-
est proportion of isolates had a MIC of 0.250 mg/L. The 
proportion of isolates with a MIC of 1 mg/L appears to 
have increased over the last few years, but the propor-
tion of isolates with a MIC ≥ 2 mg/L remained stable with 
3.3% (42/1,265) of isolates in 2011 and 3.0% (49/1,623) 
of isolates in 2015 . For cefotaxime, the biggest pro-
portion of isolates tested had a MIC ≤ 0.016 mg/L. The 
percentage of strains with higher MICs appears to 
have decreased over time, as well as the proportion 
of isolates with resistance that decreased from 4.0% 
(37/927) in 2007 to 1.9% (27/1,425) in 2015. When 
tested for ceftriaxone, most isolates also showed a 
MIC ≤ 0.016 mg/L. In 2015, four of 1,446 isolates (0.3 %) 
showed a MIC of 0.125 mg/L for ceftriaxone com-
pared to two of 1,548 (1.3 %) isolates in 2014. In con-
trast to cefotaxime, the percentage of strains with an 
increased MIC for ceftriaxone (≥ 0.032 mg/L) seems to 
have increased from 3.5% (44/1,262) in 2011 to 7.5% 
(115/1,528) in 2014, although in 2015 it decreased 
again to 4.5% (64/1,416). 
Over time, the mean MIC for cefotaxime decreased 
significantly (p < 0.0001) from 0.020 mg/L in 2007 
Figure 2
Yearly percentages of Neisseria gonorrhoeae isolates 
resistanta to ciprofloxacin, cefotaxime and azithromycin at 
Dutch sexually transmitted infection centres, 2007–2015
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a Resistant according to EUCAST breakpoints.
b Azithromycin was included in GRAS in 2011.
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to 0.008 mg/L in 2015 (Table 2). For ceftriaxone, the 
mean MIC also decreased slightly, from 0.006 mg/L 
in 2011 to 0.004 mg/L in 2015, but no trend was found 
(p = 0.96). There was a significant increase (p < 0.0001) 
in mean MIC for azithromycin, from 0.160 mg/L in 2011 
to 0.173 mg/L in 2015.
Antimicrobial resistance according to 
European committee on antimicrobial 
susceptibility testing
Figure 2  shows the percentage of isolates that were 
resistant to azithromycin, cefotaxime and ciprofloxacin 
according to EUCAST breakpoints [28]. No resistance 
to ceftriaxone was observed. The highest proportion 
of isolates with resistance was reported for ciprofloxa-
cin; however, this seems to have decreased from 52% 
of isolates (574/1,095) in 2009 to 27% (391/1,426) 
in 2015. The proportion of isolates with resistance to 
cefotaxime appears to have decreased from 10.1% 
(114/1,129) in 2010 to 1.9% (27/1,425) in 2015 and 
the proportion of isolates resistant to azithromycin 
has increased from 5.8% (80/1,369) in 2012 to 10.9% 
(176/1,623) in 2015.
Multiple drug resistance
Twenty-three isolates (6.3%; 23/366) that 
showed a decreased susceptibility for ceftriaxone 
(MIC > 0.032 mg/L) also were resistant for azithromycin 
according to EUCAST breakpoints and 118 of 366 iso-
lates (32.2%) that had a decreased susceptibility for 
ceftriaxone were also resistant for cefotaxime (Table 
3). For cefotaxime-resistant isolates, resistance for 
azithromycin was found in 18 of 532 isolates (3.4%). 
In total, 10 isolates were resistant for azithromycin 
and cefotaxime and less susceptible to ceftriaxone 
between 2007 and 2015. Highest frequencies of strains 
with decreased susceptibility and resistance to all anti-
biotics were seen in MSM (Table 3).
Determinants of cefotaxime resistance 
(MIC > 0.125mg/L)
Men who have sex with men
Among MSM, being a client of a CSW in last 6 months 
was found to be significantly associated (p = 0.007) 
with cefotaxime resistance (adjusted odds ratio (aOR): 
3.1) (Table 4).
Heterosexual men
Not using a condom during the last sexual contact 
(aOR: 0.4; p = 0.0049), receiving notification for an 
STI by a partner (aOR: 0.1; p = 0.035), 2015 as year of 
diagnosis (aOR: 0.1; p = 0.04, compared with 2007 and 
having a Chlamydia trachomatis co-infection (aOR: 0.4; 
p = 0.019) were significantly associated with cefotax-
ime susceptibility.
Women
Multivariable analysis showed a significant associa-
tion between cefotaxime resistance and oral infection 
(aOR: 2.1; p = 0.01), and having six or more partners 
(aOR: 3.5; p = 0.0006, compared with 0–2 partners).
Determinants of decreased ceftriaxone 
susceptibility (MIC > 0.032 mg/L)
Men who have sex with men
Table 5  shows that in the multivariable logistic 
regression model decreased ceftriaxone susceptibility 
was significantly associated with 2013 and 2014 as 
Table 3
Number of isolates with decreased ceftriaxone susceptibility or resistance to cefotaxime and azithromycin by sexual 
orientation, Netherlands, 2007–2015
Antibiotics
MSM 
 
(n = 7,488)
Heterosexual  
men  
 
(n = 2,526)
Women 
 
(n = 1,754)
N % N % N %
Ceftriaxonea 0 0.0 0 0.0 0 0.0
Ceftriaxone (MIC > 0.032 mg/L)b 294 3.9 30 1.2 42 2.4
Cefotaximea 410 5.5 70 2.8 52 3.0
Azithromycina 428 5.7 64 2.5 50 2.9
Azithromycin (MIC > 1 mg/L)b 152 2.0 19 0.8 16 0.9
Cefotaximea + Azithromycina 11 0.2 2 0.1 5 0.3
Ceftriaxone (MIC > 0.032 mg/L)b  + Cefotaximea 86 1.1 15 0.6 17 1.0
Ceftriaxone (MIC > 0.032 mg/L)b  + Azithromycina 17 0.2 2 0.1 4 0.2
Azithromycina + Cefotaximea + Ceftriaxone (MIC > 0.032 mg/L)b 6 0.08 1 0.0 3 0.2
EUCAST: European Committee on Antimicrobial Susceptibility Testing; MIC: minimum inhibitory concentration; MSM: men who have sex with 
men.
a Resistant according to EUCAST breakpoints: ceftriaxone resistant (MIC > 0.125 mg/L); cefotaxime resistant (MIC > 0.125 mg/L); azithromycin 
resistant (MIC > 0.5 mg/L).
b Decreased susceptibility according to breakpoint indicated in parentheses.
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Table 4
Univariable and multivariable analyses of cefotaxime resistancea of Neisseria gonorrhoeae in patients of Dutch sexually 
transmitted infection centres, by sex/sexual orientation, 2007–2015 (n = 11,643 isolates)
Characteristics
Univariable analyses OR (95% CI) Multivariable analyses aOR (95% CI)
MSM Heterosexual men Women MSM Heterosexual men Women
Year of diagnosis
2008 (vs 2007) 2.6 (1.6–4.2) 0.5 (0.2–1.8) 1.2 (0.2–6.1) 1.4 (0.4–5.4)
< 0.001 
(< 0.001–> 999) 1.0 (0.2–5.4)
2009 (vs 2007) 2.3 (1.4–3.6) 1.0 (0.4–2.6) 2.0 (0.5–7.9) 2.0 (0.5–7.6) 0.6 (0.1–3.5) 1.6 (0.4–6.4)
2010 (vs 2007) 3.3 (2.1–5.2) 0.8 (0.3–2.1) 1.3 (0.3–5.5) 4.2 (1.2–14.5) 0.6 (0.1–3.4) 1.1 (0.2–6.0)
2011 (vs 2007) 1.2 (0.8–2.1) 0.9 (0.4–2.2) 1.1 (0.3–4.5) 1.1 (0.3–3.8) 0.8 (0.2–3.5) 0.9 (0.2–4.6)
2012 (vs 2007) 0.9 (0.5–1.5) 0.5 (0.2–1.3) 0.8 (0.2–3.4) 0.8 (0.3–2.8) 0.4 (0.1–1.9) 0.8 (0.1–4.3)
2013 (vs 2007) 0.5 (0.3–0.9) 0.6 (0.2–1.7) 0.9 (0.2–3.9) 0.5 (0.1–1.6) 0.5 (0.1–2.3) 0.8 (0.2–4.2)
2014 (vs 2007) 0.6 (0.4–1.1) 0.7 (0.3–1.8) 2.2 (0.6–8.0) 0.6 (0.2–1.9) 0.6 (0.1–2.7) 2.1 (0.5–9.3)
2015 (vs 2007) 0.4 (0.2–0.8) 0.1 (0.0–0.9) 1.5 (0.4–5.9) 0.4 (0.1–1.4) 0.1 (0.0–0.9) 1.3 (0.3–6.5)
Age (years)
25–35 (vs < 25) 1.3 (0.9–1.8) 1.8 (1.0–3.4) 2.3 (1.2–4.4)
NAb NAb NAb
≥ 35 (vs < 25) 1.4 (1.0–1.9) 3.3 (1.8–6.1) 3.5 (1.8–7.0)
Other
Non-Dutch ethnicityc 0.6 (0.5–0.7) 0.8 (0.5–1.2) 1.3 (0.7–2.2) NAb NAb NAb
CSW in last 6 months  
(MSM or women) 1.2 (0.6–2.2) NA 3.3 (1.8–5.9) NA
b NAb NAb
Client of CSW in last 6 months 1.8 (0.8–4.0) 1.7 (0.9–3.1) NA 3.1 (1.4–7.2)d NA
b NAb
Previous GO/chlamydia/syphilis 1.3 (1.0–1.6) 0.9 (0.5–1.8) 0.8 (0.4–1.6) NAb NAb NAb
3–5 partners in last 6 months (vs 
0–2) 1.1 (0.8–1.6) 0.9 (0.5–1.8) 0.9 (0.4–2.4)
NAb NAb
0.9 (0.3–2.3)
≥ 6 partners in last 6 months (vs 
0–2) 1.1 (0.8–1.5) 1.5 (0.8–2.9) 4.4 (2.3–8.7) 3.5 (1.7–7.0)
Casual partner 1.0 (0.7–1.4) 2.3 (1.1–4.9) 1.1 (0.5–2.2) NAb NAb NAb
Notified of an STI by partner 0.9 (0.7–1.1) 0.3 (0.1–0.9) 1.3 (0.7–2.4) NAb 0.1 (0.0–0.9)d NAb
No condom use at last contact 0.8 (0.6–1.1) 0.5 (0.3–0.9) 0.8 (0.4–1.5) NAb 0.4 (0.2–0.8)d NAb
Urethral/cervical Neisseria 
gonorrhoeae infection 1.0 (0.8–1.3) NA
e 0.5 (0.3–0.8) NAb NAb NAb
Anal Neisseria gonorrhoeae infection 0.8 (0.7–1.0) NAf 1.4 (0.8–2.4) NAb NAb NAb
Oral Neisseria gonorrhoeae  
infection 1.0 (0.8–1.2) NA
f 2.8 (1.4–4.8) NAb NAb 2.1 (1.2–3.8)
Concurrent Ct infection 1.1 (0.8–1.3) 0.4 (0.2–0.7) 0.4 (0.2–0.8) NAb 0.4 (0.2–0.9) NAb
aOR: adjusted odds ratio; CI: confidence interval; CSW: commercial sex worker; EUCAST: European Committee on Antimicrobial Susceptibility 
Testing; GO: gonorrhoea; MIC: minimum inhibitory concentration; MSM: men who have sex with men; NA: not applicable; OR: odds ratio; 
STI: sexually transmitted infection.
a Resistant according to EUCAST breakpoint (MIC > 0.125 mg/L).
b Multivariable analyses using backward selection were only performed for variables with clinical and statistical importance (p < 0.2) in the 
univariable analyses.
c A person with both parents born in the Netherlands was considered to be of Dutch ethnicity.
d Factor not included in final model that excluded Amsterdam data.
e Number of cases in the different categories not large enough to perform analysis.
f No samples available for these sites in heterosexual men.
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year of diagnosis (aOR: 2.1; p = 0.0005; aOR: 2.1; 
p = 0.0004, compared with 2011), and non-Dutch eth-
nicity (aOR: 1.9; p = 0.0004). Urethral and anal infec-
tions were found to be significantly associated with 
ceftriaxone susceptibility (aOR: 0.5; p < 0.0001; aOR: 
0.6; p < 0.0001).
For heterosexual men and women, only univariable 
analyses were performed because of the small number 
of isolates with an MIC > 0.032 mg/L.
Heterosexual men
Univariable analyses show that being over 35 years 
of age (OR: 5.4; p = 0.0007) and having a casual sex 
partner (OR: 2.7; p = 0.0291) were associated with a 
decreased susceptibility to ceftriaxone among hetero-
sexual men. Having a co-infection with  C. trachoma-
tis  (OR: 0.4; p = 0.0251) and not using a condom at 
one’s last sexual encounter (OR: 0.4; p = 0.0119) were 
associated with susceptibility to ceftriaxone.
Women
In the univariable analysis, decreased susceptibility to 
ceftriaxone was associated with 2014 and 2015 as year 
of diagnosis (OR: 4.8; p = 0.0048; OR: 3.4; p = 0.0368, 
compared with 2011), being over 35 years-old (OR: 4.0; 
p = 0.0002), a non-Dutch ethnicity (OR: 2.3; p = 0.0338), 
working as a CSW (OR: 4.2; p < 0.0001), having six or 
Table 5
Univariable and multivariable analyses of decreased ceftriaxone susceptibilitya of Neisseria gonorrhoeae in patients of Dutch 
sexually transmitted infection centres, by sex/sexual orientation, 2011–2015 (n = 6,884 isolates)
Characteristics
Univariable analyses OR (95% CI) Multivariable analyses aOR (95% CI)
MSM Heterosexual men Women MSM
Year of diagnosis
2012 (vs 2011) 1.1 (0.7–1.8) 0.9 (0.3–2.8) 0.6 (0.1–3.2) 1.1 (0.7–1.7)
2013 (vs 2011) 2.1 (1.4–3.2) 1.2 (0.4–3.9) 1.4 (0.4–5.2) 2.1 (1.4–3.2)
2014 (vs 2011) 2.0 (1.3–3.0) 1.5 (0.5–4.3) 4.8 (1.6–14.4) 2.1 (1.4–3.2)
2015 (vs 2011) 1.1 (0.7–1.7) 0.6 (0.2–2.6) 3.4 (1.1–10.7) 1.2 (0.7–1.8)
Age (years)
25–35 years (vs < 25 years) 0.8 (0.6–1.1) 2.2 (0.8–5.9) 1.1 (0.5–2.5) NAb
≥ 35 years (vs < 25 years) 0.9 (0.6–1.2) 5.4 (2.0–14.4) 4.0 (1.9–8.2) NAb
Other
Non-Dutch ethnicityc 2.0 (1.4–2.9) 0.8 (0.3–1.7) 2.3 (1.1–5.1) 1.9 (1.3–2.7)d
CSW in last 6 months 
(MSM or women) 0.7 (0.3–1.7) NA 4.2 (2.2–8.1) NA
b
Client of CSW in last 6 months 1.7 (0.6–4.2) 1.3 (0.4–3.9) NA NAb
Previous GO/chlamydia/syphilis 1.1 (0.9–1.5) 0.4 (0.1–1.6) 1.0 (0.8–2.1) NAb
3–5 partners in last 6 months (vs 0–2) 0.8 (0.5–1.2) 1.2 (0.4–3.0) 1.7 (0.7–4.2)
NAb
≥ 6 partners in last 6 months (vs 0–2) 0.9 (0.6–1.2) 0.4 (0.2–1.6) 6.2 (3.0–12.8)
Casual partner 1.2 (1.0–1.6) 2.7 (1.1–6.7) 1.1 (0.6–2.1) NAb
Notified of an STI by partner 1.1 (0.8–1.4) 0.6 (0.2–1.6) 1.2 (0.6–2.2) NAb
No condom use at last contact 0.7 (0.6–0.9) 0.4 (0.2–0.8) 0.4 (0.2–0.8) NAb
Urethral/cervical Neisseria 
gonorrhoeae infection 0.6 (0.5–0.8) NA
e 0.4 (0.2–0.7) 0.5 (0.4–0.7)d
Anal Neisseria gonorrhoeae infection 0.8 (0.6–1.0) NAf 2.2 (1.2–4.2) 0.6 (0.4–0.8)d
Oral Neisseria gonorrhoeae infection 1.2 (0.9–1.5) NAf 2.0 (1.1–3.8) NAb
Concurrent Ct infection 0.9 (0.7–1.2) 0.4 (0.1–0.9) 0.6 (0.3–1.2) NAb
aOR: adjusted odds ratio; CI: confidence interval; CSW: commercial sex worker; EUCAST: European Committee on Antimicrobial Susceptibility 
Testing; GO: gonorrhoea; MIC: minimum inhibitory concentration; MSM: men who have sex with men; NA: not applicable; OR: odds ratio; 
STI: sexually transmitted infection.
For heterosexual men and women, only univariable analyses were performed because of the small number of isolates with an MIC > 0.032 mg/L.
a Decreased ceftriaxone susceptibility according to breakpoint (MIC > 0.032 mg/L).
b Multivariable analyses using backward selection were only performed for variables with clinical and statistical importance (p < 0.2) in the 
univariable analyses.
c A person with both parents born in the Netherlands was considered to be of Dutch ethnicity.
d Factor not included in final model that excluded Amsterdam data.
e Number of cases in the different categories not large enough to perform analysis.
f No samples available for these sites in heterosexual men.
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more partners (OR: 6.2; p < 0.0001, compared with 
0–2 partners), and anal and oral infections (OR: 2.2; 
p = 0.01; OR: 2.0; p = 0.0289). A urethral or cervical 
infection (OR: 0.4; p = 0.0019) and not using a condom 
at one’s last sexual encounter (OR: 0.4; p = 0.0125) 
were found to be associated with ceftriaxone suscep-
tibility for women.
Determinants for azithromycin resistance 
(MIC > 0.5 mg/L)
Men who have sex with men
In the multivariable logistic analysis, 2012, 2013, and 
2014 as year of diagnosis (aOR: 0.6; p = 0.0035; aOR: 
0.6; p = 0.012; aOR: 0.7; p = 0.013, compared with 
2011), being over 35 years of age (aOR: 0.7; p = 0.01) 
and a non-Dutch ethnicity (aOR: 0.1; p < 0.0001) were 
Table 6
Univariable and multivariable analyses of azithromycin resistancea of Neisseria gonorrhoeae in patients of Dutch sexually 
transmitted infection centres, by sex/sexual orientation, 2011–2015 (n = 6,893 isolates)
Characteristics
Univariable analyses OR (95% CI) Multivariable analyses aOR (95% CI)
MSM Heterosexual men Women MSM Heterosexual men Women
Year of diagnosis
2012 (vs 2011) 0.6 (0.4–0.9) 2.3 (0.9–6.1) 0.9 (0.3–2.2) 0.6 (0.4–0.8) 2.0 (0.8–5.4) 0.8 (0.3–2.2)
2013 (vs 2011) 0.7 (0.5–1.0) 2.6 (1.0–7.1)      1.1 (0.5–2.6) 0.6 (0.4–0.9) 2.3 (0.8–6.3)
1.0 
(0.4–2.3)
2014 (vs 2011) 0.9 (0.7–1.2) 2.4 (0.9–6.3)      1.0 (0.4–2.4) 0.7 (0.5–0.9) 1.8 (0.7–5.0)
0.8 
(0.3–1.9)
2015 (vs 2011) 1.5 (1.1–1.9) 3.9 (1.5–10.0) 0.8 (0.3–2.0) 1.0 (0.7–1.3) 2.5 (0.9–6.6) 0.5 (0.2–1.3)
Age (years)
25–35 (vs < 25) 0.7 (0.6–1.0) 2.4 (1.3–4.4) 1.5 (0.8–3.1) 0.9 (0.7–1.1) 2.5 (1.3–4.6) NAb
≥ 35 (vs < 25) 0.6 (0.5–0.8) 2.7 (1.3–5.3) 2.7 (1.3–5.6) 0.7 (0.5–0.9) 2.6 (1.3–5.4) NAb
Other
Non-Dutch ethnicityc 0.1 (0.1–0.2) 0.3 (0.1–0.4) 0.4 (0.2–0.7) 0.1 (0.1–0.2) 0.3 (0.2–0.5)d 0.3 (0.2–0.6)d
CSW in last 6 months (MSM or 
women) 0.3 (0.1–0.9) NA 1.9 (0.9–3.7) NA
b NAb NAb
Client of CSW in last 6 months 0.6 (0.2–2.0) 1.2 (0.6–2.6) NA NAb NAb NAb
Previous GO/chlamydia/syphilis 1.0 (0.8–1.3) 0.8 (0.4–1.8) 1.2 (0.6–2.4) NAb NAb NAb
3–5 partners in last 6 months (vs 
0–2) 0.8 (0.6–1.1) 1.8 (1.0–3.2) 0.6 (0.3–1.5) NA
b 2.2 (1.2–3.8) NAb
≥ 6 partners in last 6 months (vs 
0–2) 0.6 (0.5–0.8) 1.1 (0.5–2.3) 1.9 (1.0–3.6) NA
b 1.2 (0.5–2.5) NAb
Casual partner 1.1 (0.9–1.3) 1.4 (0.8–2.4) 0.9 (0.5–1.6) NAb NAb NAb
Notified of an STI by partner 0.9 (0.7–1.1) 0.6 (0.3–1.2) 0.9 (0.5–1.6) NAb NAb NAb
No condom use at last contact 0.6 (0.5–0.8) 0.5 (0.3–0.9) 0.5 (0.3–1.0) NAb NAb NAb
Urethral/cervical Neisseria 
gonorrhoeae infection 1.2 (1.0–1.4) NA
e 1.1 (0.5–2.5) NAb NAb NAb
Anal Neisseria gonorrhoeae 
infection 1.1 (0.9–1.3) NA
f 0.7 (0.3–1.3) NAb NAb NAb
Oral Neisseria gonorrhoeae 
infection 1.3 (1.0–1.6) NA
f 2.3 (1.3–4.1) NAb NAb 2.1 (1.2–3.9)d
Concurrent Ct infection 1.0 (0.8–1.3) 0.8 (0.5–1.4) 0.2 (0.1–0.5) NAb NAb 0.3 (0.1–0.5)
aOR: adjusted odds ratio; CI: confidence interval; CSW: commercial sex worker; EUCAST: European Committee on Antimicrobial Susceptibility 
Testing; GO: gonorrhoea; MIC: minimum inhibitory concentration; MSM: men who have sex with men; NA: not applicable; OR: odds ratio; 
STI: sexually transmitted infection.
a Resistance according to EUCAST breakpoint (MIC > 0.5 mg/L).
b Multivariable analyses using backward selection were only performed for variables with clinical and statistical importance (p < 0.2) in the 
univariable analyses.
c A person with both parents born in the Netherlands was considered to be of Dutch ethnicity.
d Factor not included in final model, excluding Amsterdam data.
e Number of cases in the different categories not large enough to perform analysis.
f No samples available for these sites in heterosexual men.
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significantly associated with azithromycin susceptibil-
ity (Table 6).
Heterosexual men
For heterosexual men, being older than 25 years (aOR: 
2.5; p = 0.0049; aOR: 2.6; p = 0.0079) and having three 
to five partners (aOR: 2.2; p = 0.01, compared with 0–2 
partners) were significantly associated with azithro-
mycin resistance in the multivariable analysis. A non-
Dutch ethnicity (aOR: 0.3, p < 0.0001) was significantly 
associated with azithromycin susceptibility.
Women
Having an oral gonorrhoea infection was significantly 
associated with azithromycin resistance in the multi-
variable analysis (aOR: 2.1; p = 0.0227). A non-Dutch 
ethnicity (aOR: 0.3, p = 0.0009) and a  C. trachoma-
tis co-infection (aOR: 0.3; p = 0.0004) were significantly 
associated with azithromycin susceptibility.
Analyses without data from Amsterdam
Because there was a heavy influence of data submit-
ted from Amsterdam (61.3% of all isolates between 
2007 and 2015 came from Amsterdam) and it is known 
that a higher-risk population (73.6% MSM [26]) is 
being tested at the STI centre in Amsterdam, the analy-
ses were repeated without these data and some dif-
ferences were found. The multivariable analyses of 
MSM outside Amsterdam showed that being a client 
of a CSW was no longer associated with cefotaxime 
resistance (Table 4). For heterosexual men, receiving 
notification for an STI and not using a condom dur-
ing the last sexual contact were no longer associated 
with susceptibility in the cefotaxime multivariable 
model. Urethral and anal infections were not associ-
ated with susceptibility to ceftriaxone in this multivari-
able model, and a non-Dutch ethnicity was no longer 
associated with decreased ceftriaxone susceptibility 
for MSM outside Amsterdam (Table 5). For azithromy-
cin resistance, among women, there was no longer an 
association with an oral infection, and a non-Dutch 
ethnicity was no longer associated with azithromycin 
susceptibility (Table 6). A non-Dutch ethnicity was also 
not associated with susceptibility to azithromycin for 
heterosexual men.
Discussion
Analysis of GRAS, the nationwide surveillance network 
focused on  N.  gonorrhoeae  resistance, shows that 
resistance to ceftriaxone has not yet been reported 
in the Netherlands, despite the current increase 
of ceftriaxone resistance outside the Netherlands 
[25,29,30]. The proportion of isolates with a decreased 
susceptibility to ceftriaxone (MIC > 0.032 mg/L) varied 
over time; it increased from 3.5% in 2011 to 7.5% in 
2014, but decreased again to 4.5% in 2015. No signifi-
cant trend over time was found.
Although azithromycin is not included in routine treat-
ment of gonorrhoea in the Netherlands, there was a 
significant increase (p < 0.0001) in mean MIC for azithro-
mycin, and resistance to azithromycin has increased 
to 10.9% in 2015. The proportion of isolates with 
high-level resistance to azithromycin (MIC  ≥ 2.0 mg/L) 
has remained stable over the years with 3.3% of iso-
lates in 2011 and 3.0% of isolates in 2015, however, 
the increase in low-level azithromycin resistance 
(MIC = 1.0 mg/L) since 2014 could lead to an increase 
in higher resistant strains in the future. It could well be 
that a significant proportion of STI centre patients with 
gonorrhoea have undergone syndromic treatment for 
urethritis, including azithromycin, as the initial treat-
ment procedure for urethritis with a low suspected risk 
of  N.gonorrhoeae  infection is 1,000 mg azithromycin 
[15]. This could explain low-level resistance, since it 
has recently been shown that  N. gonorrhoeae  strains 
cultured shortly after azithromycin treatment had 
increased MICs against azithromycin in comparison to 
other strains [31].
Cefotaxime was used as first-line treatment in the 
Netherlands up to 2006 and the proportion of iso-
lates resistant to cefotaxime has decreased from 4.0% 
in 2007 to 1.9% in 2015. Interestingly, only 22.2% 
of strains with cefotaxime resistance also showed 
decreased susceptibility to ceftriaxone and alterna-
tively, only 32.2% of strains with decreased suscep-
tibility to ceftriaxone were resistant to cefotaxime, 
suggesting that different molecular mechanisms might 
be responsible for resistance against different 3G 
cephalosporins. On the other hand, there are no uni-
versally agreed breakpoints for decreased susceptibil-
ity to ceftriaxone and for cefotaxime resistance (e.g. 
the Clinical and Laboratory Standards Institute (CLSI) 
uses a higher breakpoint (MIC > 0.5 mg/L) [32] than 
EUCAST (MIC > 0.125 mg/L) for cefotaxime), so it cannot 
be ruled out that the breakpoints chosen in this study 
could also have contributed to discrepancies in the 
proportion of isolates resistant to cefotaxime that are 
also less susceptible to ceftriaxone and vice versa.
So far, these data support the Dutch decision to use 
ceftriaxone monotherapy for gonorrhoea instead of 
dual therapy with azithromycin; no resistance to ceftri-
axone has been found since its introduction in 2006 
while resistance to azithromycin is increasing.
When looking at determinants associated with 
decreased susceptibility of antibiotics used for treat-
ment of gonorrhoea, differences were observed 
between people with different sexual behaviour. For 
women, the predominant determinant of decreased 
susceptibility of gonorrhoea was an oral infection; 
gonorrhoea in the pharynx was associated with resist-
ance to azithromycin and cefotaxime. Also in MSM, 
oral infection was a risk factor for azithromycin resist-
ance in the univariable analysis. Pharyngeal gonococ-
cal infections are considered a potential reservoir for 
resistant isolates. It is thought that N. gonorrhoeae can 
become resistant through DNA acquisition from 
commensal  Neisseria  species, which could have been 
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selected for by the lower efficacy of cephalosporins 
in the pharynx [24,33-35]. In the univariable analysis, 
isolates of women working as CSW were also associ-
ated with resistance to cefotaxime, as was the case 
in the univariable analyses on decreased susceptibil-
ity of ceftriaxone. However, working as a CSW was not 
significantly associated with gonococcal resistance in 
the multivariable analyses. Instead, having six or more 
sex partners was associated with resistance to cefo-
taxime, though number of sex partners can be consid-
ered a good proxy for sex work. A study on sexually 
transmitted infections among female sex workers in 
the Netherlands showed that of all gonorrhoea infec-
tions, oral infections were most commonly diagnosed 
(52.4%) [36]. Healthcare workers associated with the 
project also recognised that female CSW often do not 
use a condom when performing oral sex because they 
can charge a higher fee for this service. In this study, 
56.2% of female CSW were diagnosed with oral infec-
tions vs 24.2% of women not working as sex work-
ers. As pharyngeal gonorrhoea infections appear to 
be common among female CSW, emerging resistance 
of gonorrhoea in the pharynx in this risk group should 
continue to be carefully monitored.
Isolates of heterosexual men and women susceptible 
to cefotaxime, ceftriaxone or azithromycin were asso-
ciated with a concurrent C. trachomatis  infection. This 
has also been found by Cole et al. in isolates from Euro-
GASP showing resistance to cefixime and ciprofloxacin 
[37]. Studies have been performed looking at the inter-
action between gonorrhoea and chlamydia [38-40] but 
a biological mechanism responsible for this manifesta-
tion has not been identified. A possible explanation for 
this association between resistance and a chlamydial 
co-infection could be a decrease in fitness of the  N. 
gonorrhoeae  when it has higher resistance levels and 
consequently preferential growth of chlamydia after 
co-infections with chlamydia and resistant  N.  gon-
orrhoeae  strains. Bacteria are well known to be able 
to occupy a particular niche if they can better adapt 
to existing conditions. This mechanism is known e.g. 
in meticillin-resistant  Staphylococcus aureus  (MRSA) 
compared with non-resistant  Staphylococcus 
aureus  and various studies have demonstrated this 
relation between fitness and resistance levels [41-43].
Like Trecker et al. [44] and McLean et al. [45] but in 
contrast to Town et al. [46], our study showed a sig-
nificant association with age: for heterosexual men, 
being older than 25 years of age was significantly asso-
ciated with resistance to azithromycin and being older 
than 35 years of age was associated with decreased 
susceptibility to ceftriaxone. We also found a signifi-
cant association with a higher number of sex partners 
(3–5 partners) and resistance to azithromycin among 
heterosexual men. The use of a condom during the last 
sexual contact by heterosexual men was associated 
with resistance to cefotaxime and in the univariable 
analysis with decreased susceptibility to ceftriaxone. A 
possible explanation could have to do with the time of 
observation: people visit the STI centre when there is 
an indication to do so. Possibly, heterosexual men who 
visit an STI centre suspect an STI and will have used 
condoms immediately before the visit. This reversed 
effect was previously shown in the Netherlands in 
MSM attaining a gonorrhoea infection [47].
Evidence of a decrease in azithromycin susceptibility 
in Europe has been reported in recent years [29,37,46], 
although contrary findings have also been reported. 
Wind et al. [26] report that azithromycin resistance 
remained stable around 1.2% in their Amsterdam study 
population, although the percentage of isolates with 
intermediate MICs (MIC > 0.25 to ≤ 0.5 mg/L) increased 
from 3.7% in 2012 to 15.6% in 2014. We only found an 
association between resistance to azithromycin and 
2015 as year of diagnosis in univariable analyses, spe-
cifically among heterosexual men and MSM. We did, 
nevertheless, observe a significant increase in azithro-
mycin MIC over time (p < 0.0001) and an increase in per-
centage of azithromycin resistance to 10.9% in 2015. 
The difference in azithromycin susceptibility between 
the national and Amsterdam data lies in the propor-
tion of isolates with low-level resistance (MIC > 0.5 mg/L 
to ≤ 1 mg/L), which is higher in the Netherlands overall. 
This could possibly be explained by differences in lab-
oratory techniques such as the use of different media 
for N. gonorrhoeae culture.
In addition, we found an association between a non-
Dutch ethnicity and decreased ceftriaxone susceptibil-
ity in MSM, in contrast to the association of a non-Dutch 
ethnicity with azithromycin susceptibility among MSM.
There are some limitations to this study. Firstly, for only 
42.0% of all gonorrhoea diagnoses an isolate tested for 
susceptibility was available. This can be explained in 
part by negative cultures following an initial PCR diag-
nosis and either self-clearance or syndromic antibiotic 
treatment. In these patients, susceptibility testing is 
not possible. Overall, about half of the anal and cer-
vical cultures was negative (50.3% and 51.1% respec-
tively), the percentage of negative urethral cultures was 
slightly lower (39.8%) while the highest percentage of 
negative cultures was for oral cultures (72.2%). These 
negative cultures could also explain why patients with 
an isolate differed from patients without an isolate 
regarding their demographic characteristics. In addi-
tion, it was not possible to report the results of more 
than one culture per patient to GRAS.
Secondly, isolates were selected based on new consul-
tations. Since June 2014, an ID number has been avail-
able in SOAP and analysing the data from June 2014 
until December 2015, we found that some patients were 
included multiple times (15.2%). This could have influ-
enced our results if a strain was included more than 
once due to patients being re-infected by the same 
untreated partner with the same strain.
Thirdly, there is a heavy influence of data submitted 
from Amsterdam; 61.3% of all isolates between 2007 
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and 2015 came from Amsterdam. Analyses without the 
data from Amsterdam gave partially different results; 
this is probably due to the higher-risk population 
(73.6% MSM) that is being tested at the STI centre in 
Amsterdam [26].
Furthermore, no form of molecular typing was per-
formed in this study. The results on possible gonor-
rhoea resistance were only confirmed with an Etest. 
Possible links to known clusters or clones could there-
fore not be identified. Finally, we do not know the 
situation regarding resistance of  N. gonorrhoeae  at 
the general practitioner (GP). Because of the logistics 
associated with GRAS, GPs do not participate in this 
surveillance, and GRAS surveillance assumes that 
resistance is most likely to emerge and spread first in 
the high-risk population seen at the STI centres.
In conclusion, resistance to ceftriaxone has not been 
detected yet in the Netherlands and no significant 
trend in MICs over time has been found; however, a 
significant increase in MIC for azithromycin over time 
has been identified. The current understanding of 
possible determinants for antimicrobial resistance 
in  N. gonorrhoeae  in the Netherlands is limited and 
identifying risk factors for AMR infections could help 
determine evidence-based risk groups and subsequent 
focused treatments or public health intervention 
strategies. Targeted surveillance of new resistance 
patterns and insights into sexual networks and 
determinants is essential. To continue improving the 
AMR surveillance for gonorrhoea in the Netherlands, 
GRAS has been expanded allowing for more than one 
culture per patient to be reported starting in 2016. 
Further optimisation of GRAS could be the inclusion of 
culture results from GPs. In addition, the development 
of new treatment strategies and reassessment of older 
antimicrobial agents is necessary to prevent severe 
public health consequences.
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